Announcements Trials
Browse Landscape

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 37Observational 2

Sponsor

Cancer Type

Genitourinary 2Gynecologic 1

Conditions

Prostatic Neoplasms 2

Interventions

Surveys and Questionnaires 52Blood Specimen Collection 47enzalutamide 29radium Ra 223 dichloride 22Biopsy 20darolutamide 19Radiotherapy 19Docetaxel 19apalutamide 18Sunitinib 18Magnetic Resonance Spectroscopy 18Sorafenib 17Abiraterone Acetate 17Watchful Waiting 16Interviews as Topic 15Gene Expression Profiling 15Amplified Fragment Length Polymorphism Analysis 15Observation 13Leuprolide 13Immunohistochemistry 13Androgen Antagonists 13acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 12Magnetic Resonance Imaging 12avelumab 11Specimen Handling 11abiraterone 9Polymerase Chain Reaction 9Flow Cytometry 9Radiosurgery 8Microarray Analysis 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × relugolix × Genitourinary × Clear all
NCT05467176 2026-04-08

OPTYX

Sumitomo Pharma America, Inc.

Active not recruiting
999 enrolled
Genitourinary

Prostatic Neoplasms

NCT06462014 2025-12-11

Description of Relugolix Use in Patients With Prostate Cancer Within the VHA

Pfizer

Completed
507 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡